Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II Study of Anti-PD-1/LAG-3 Bispecific Antibody AK129 Combinations in Advanced Solid Tumors

NCT06943820 is registered in ClinicalTrials.gov with Akeso as lead sponsor.

NCT NCT06943820
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06943820 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II Study of Anti-PD-1/LAG-3 Bispecific Antibody AK129 Combinations in Advanced Solid Tumors
Lead sponsor
Akeso
Phase
Phase 1/2
Overall status
Recruiting
Start date
May 21, 2025
Completion date
May 31, 2028
Enrollment
230 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors, colorectal adenocarcinoma, head and neck squamous cell carcinoma (hnscc), non-small cell lung cancer stage iiib/iv